Company Overview

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and autoimmune diseases. The company operates within the biotechnology and pharmaceutical industries, with an emphasis on precision medicine approaches that leverage deep biological insights. Cullinan’s strategy centers on advancing a diversified portfolio of drug candidates across multiple programs rather than a single-asset model, aiming to reduce development risk while addressing areas of high unmet medical need.

Founded in 2018, Cullinan Therapeutics was established to build and scale multiple innovative therapeutic programs simultaneously through a centralized operating platform. Since inception, the company has progressed several candidates into clinical development, evolving from an early-stage pipeline builder into a publicly traded clinical-stage company listed on Nasdaq under the ticker CGEM. Its positioning is distinguished by a hub-and-spoke model that combines shared infrastructure with program-specific scientific leadership.

Business Operations

Cullinan Therapeutics conducts its operations primarily through a portfolio of oncology and immunology programs, each focused on a specific molecular target or pathway. The company does not currently generate commercial revenue; its activities are centered on research and development, including preclinical research, clinical trials, and regulatory preparation. Key development-stage assets include programs targeting B-cell malignancies, solid tumors, and immune-mediated diseases.

Operations are supported by internal research capabilities and extensive use of third-party contract research organizations for clinical trial execution and manufacturing. The company controls intellectual property related to its drug candidates and development platforms, while also leveraging in-licensed technologies. Cullinan’s business model emphasizes capital allocation across programs based on clinical data and strategic priority rather than geographic revenue segmentation.

Strategic Position & Investments

Cullinan’s strategic direction is focused on advancing multiple clinical-stage assets toward proof-of-concept data while maintaining flexibility to prioritize or discontinue programs based on results. Growth initiatives include progressing lead candidates through mid-stage clinical trials and selectively expanding the pipeline through internal research or external licensing opportunities. The company has historically used acquisitions and asset purchases to build its portfolio, including the acquisition of rights to targeted oncology compounds from third parties.

The company’s portfolio includes notable subsidiaries and program-specific entities such as Cullinan Pearl, Cullinan Apollo, and Cullinan Mica, each associated with distinct therapeutic candidates. Cullinan is actively involved in emerging areas such as targeted protein degradation, antibody-based therapies, and precision oncology, reflecting its focus on scientifically differentiated approaches.

Geographic Footprint

Cullinan Therapeutics is headquartered in Cambridge, Massachusetts, within a major global biotechnology hub. Its primary operations, including executive leadership and research oversight, are based in the United States. Clinical development activities, however, have an international footprint, with clinical trials conducted across North America, Europe, and parts of Asia, depending on the specific program and indication.

While the company does not maintain large international commercial offices, its global presence is reflected through multinational clinical trial sites, regulatory interactions with non-U.S. authorities, and relationships with international research institutions. This global operational reach supports patient recruitment and regulatory strategy across multiple jurisdictions.

Leadership & Governance

Cullinan Therapeutics is led by an executive team with experience in biotechnology, pharmaceuticals, and capital markets. The leadership emphasizes disciplined capital allocation, scientific rigor, and data-driven decision-making as core elements of the company’s strategic vision. Governance is overseen by a board of directors with backgrounds in drug development, finance, and corporate leadership.

Key executives include:

• Nadim Ahmed – President and Chief Executive Officer
• Jeffrey Jones – Chief Financial Officer
• David Lubner – Chief Development Officer
• Patrick Baeuerle – Chief Scientific Officer

The leadership team’s philosophy centers on building long-term value through a diversified pipeline, maintaining operational efficiency, and advancing programs with clear biological rationale and clinical differentiation.